Several characteristics, such as older age, white race, low body weight, low nadir CD4+ T cell count, long duration of ART and exposure of protease inhibitors (PIs), or some nucleoside reverse transcriptase inhibitors (NRTIs) have been identified as risk factors for HALS.[1] This syndrome is also associated with metabolic abnormalities such as dyslipidemia, insulin resistance, and glucose intolerance. This evidence concerns the gene CD4 and metabolic syndrome.